Eli Lilly and Company (NYSE:LLY) is Kampmann Melissa S.’s Largest Position

Kampmann Melissa S. decreased its position in Eli Lilly and Company (NYSE:LLY) by 8.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,986 shares of the company’s stock after selling 889 shares during the quarter. Eli Lilly and Company makes up 6.6% of Kampmann Melissa S.’s portfolio, making the stock its biggest holding. Kampmann Melissa S.’s holdings in Eli Lilly and Company were worth $9,041,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Aveo Capital Partners LLC raised its holdings in Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after acquiring an additional 153 shares during the period. J. W. Coons Advisors LLC grew its position in shares of Eli Lilly and Company by 4.0% during the fourth quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 90 shares in the last quarter. Jones Financial Companies Lllp raised its stake in Eli Lilly and Company by 27.9% during the 4th quarter. Jones Financial Companies Lllp now owns 9,024 shares of the company’s stock valued at $5,260,000 after purchasing an additional 1,967 shares during the period. CWA Asset Management Group LLC lifted its holdings in Eli Lilly and Company by 32.7% in the 4th quarter. CWA Asset Management Group LLC now owns 3,272 shares of the company’s stock worth $1,907,000 after purchasing an additional 807 shares in the last quarter. Finally, NEOS Investment Management LLC boosted its stake in Eli Lilly and Company by 65.7% in the 4th quarter. NEOS Investment Management LLC now owns 12,673 shares of the company’s stock worth $7,387,000 after purchasing an additional 5,025 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Bank of America lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Jefferies Financial Group increased their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Finally, Deutsche Bank Aktiengesellschaft raised Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their target price for the stock from $725.00 to $1,025.00 in a report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $877.79 on Monday. The business’s 50 day moving average price is $896.10 and its 200-day moving average price is $844.12. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The company has a market cap of $834.26 billion, a P/E ratio of 129.28, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Sell-side analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total value of $8,098,662.88. Following the sale, the insider now directly owns 97,299,772 shares of the company’s stock, valued at approximately $89,059,454,309.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 364,810 shares of company stock worth $339,366,198. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.